Nebulisation of surfactants in an animal model of neonatal respiratory distress
- PMID: 9536832
- PMCID: PMC1720731
- DOI: 10.1136/fn.78.1.f3
Nebulisation of surfactants in an animal model of neonatal respiratory distress
Abstract
Aims: To evaluate pulmonary deposition and gas exchange following nebulisation of two surfactants by either a jet or an ultrasonic nebuliser.
Method: After bronchoalveolar lavage (BAL), 19 rabbits were ventilated in four groups. Group A1 (n = 5) and A2 (n = 6) received Technetium-99m labelled Exosurf, and groups B1 (n = 4) and B2 (n = 4) received radiolabelled Survanta. Groups A1 and B1 received jet nebuliser therapy, whereas groups A2 and B2 received ultrasonic nebuliser. Pulmonary deposition, distribution, and blood gases were determined.
Results: Pulmonary deposition as per cent of initial dose and mg lipid) was 0.28(0.10)% or 0.59(0.21) mg in group A1, 1.05(0.23)% or 2.21(0.48) mg in group A2, 0.08(0.02)% or 0.30(0.08) mg in group B1, and 0.09(0.02)% or 0.34(0.08) mg in group B2. Deposition in group A2 was greater than in other groups (p = 0.001). Group A2 showed a small improvement in blood gases.
Conclusions: Even the highest deposition--ultrasonic nebuliser with Exosurf--achieved limited clinical effect. The aerosol route is currently not effective for surfactant treatment.
Similar articles
-
Comparative efficacy of exosurf and survanta surfactants on early clinical course of respiratory distress syndrome and complications of prematurity.J Perinatol. 1997 Nov-Dec;17(6):455-60. J Perinatol. 1997. PMID: 9447532 Clinical Trial.
-
Comparison of the changes in the a/A oxygen ratio after administration of two surfactants for the treatment of neonatal respiratory distress syndrome.J Trop Pediatr. 1997 Feb;43(1):38-41. doi: 10.1093/tropej/43.1.38. J Trop Pediatr. 1997. PMID: 9078827 Clinical Trial.
-
Effect of inhaled surfactant on pulmonary deposition and clearance of technetium-99m-DTPA radioaerosol.J Nucl Med. 1998 Mar;39(3):543-7. J Nucl Med. 1998. PMID: 9529308
-
Dose-response comparisons of five lung surfactant factor (LSF) preparations in an animal model of adult respiratory distress syndrome (ARDS).Br J Pharmacol. 1995 Jun;115(3):451-8. doi: 10.1111/j.1476-5381.1995.tb16354.x. Br J Pharmacol. 1995. PMID: 7582456 Free PMC article.
-
Colfosceril palmitate. A review of the therapeutic efficacy and clinical tolerability of a synthetic surfactant preparation (Exosurf Neonatal) in neonatal respiratory distress syndrome.Drugs. 1991 Nov;42(5):877-94. doi: 10.2165/00003495-199142050-00009. Drugs. 1991. PMID: 1723378 Review.
Cited by
-
Update of minimally invasive surfactant therapy.Korean J Pediatr. 2017 Sep;60(9):273-281. doi: 10.3345/kjp.2017.60.9.273. Epub 2017 Sep 21. Korean J Pediatr. 2017. PMID: 29042870 Free PMC article. Review.
-
Aerosolized Surfactant for Preterm Infants with Respiratory Distress Syndrome.Children (Basel). 2021 Jun 10;8(6):493. doi: 10.3390/children8060493. Children (Basel). 2021. PMID: 34200535 Free PMC article. Review.
-
Dose-Response Study on Surfactant Nebulization Therapy During Nasal Continuous Positive Airway Pressure Ventilation in Spontaneously Breathing Surfactant-Deficient Newborn Piglets.Pediatr Crit Care Med. 2020 Jul;21(7):e456-e466. doi: 10.1097/PCC.0000000000002313. Pediatr Crit Care Med. 2020. PMID: 32195907 Free PMC article.
-
Nebulised surfactant in preterm infants with or at risk of respiratory distress syndrome.Cochrane Database Syst Rev. 2012 Oct 17;10(10):CD008310. doi: 10.1002/14651858.CD008310.pub2. Cochrane Database Syst Rev. 2012. PMID: 23076945 Free PMC article.
-
Development of a New Dry Powder Aerosol Synthetic Lung Surfactant Product for Neonatal Respiratory Distress Syndrome (RDS) - Part II: In vivo Efficacy Testing in a Rabbit Surfactant Washout Model.Pharm Res. 2024 Sep;41(9):1827-1842. doi: 10.1007/s11095-024-03754-7. Epub 2024 Sep 5. Pharm Res. 2024. PMID: 39237797 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources